Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2013

View Archived Issues

New anticancer agents prepared by Bayer

Wacker develops production process for Metheresis' anticancer candidate

New liposomal nanoparticle formulation tested for activity in ovarian cancer

ALT-801 evaluated in phase I/II trial in patients with urothelial cancer

Spanish researchers disclose new calpain inhibitors

Evestra discloses novel progesterone receptor antagonists

Eli Lilly discloses novel notch signaling inhibitors

FDA accepts umeclidinium bromide/vilanterol NDA

KBP BioSciences synthesizes new antibacterial agents

Intra-Cellular Therapies completes phase I trial of ITI-214

Isis Pharmaceuticals begins phase II/III study of ISIS-TTRRx

Peregrine Pharmaceuticals updates topline data from bavituximab trial

Reduction in tumor burden found with ALT-803 in rodent models

Sucampo launches Rescula in the U.S.

Nippon Kayaku files for additional approval of Hycamtin in Japan

Merck & Co. presents new inhibitors of mTORC1/2

Antiproliferative activity demonstrated for palbociclib in RCC cells

German scientists synthesize novel glycine transporter inhibitors

Stem Cell Therapeutics enters joint-venture agreement

Encouraging immunogenicity results reported from phase III program for NX-1207

C3 Jian completes enrollment for phase I study of candidate for cavity prevention

Phase III data further support efficacy of sofosbuvir

Two novel antibodies enhance response to chemotherapy in NSCLC

Galectin Therapeutics to collaborate with the University of Georgia on drug discovery

Ono files additional indication application for Onoact 50 for injection in Japan

AcelRx Pharmaceuticals provides update on trials of sufentanil NanoTab system